Opposite effects of ANP receptors in attenuation of LPS-induced endothelial permeability and lung injury

Microvascular Research

Volumn 83, Issue 2, 2012, Pages 194-199

  Xing, Junjie ^a   Yakubov, Bakhtiyor ^a   Poroyko, Valeriy ^a   Birukova, Anna A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; LIPOPOLYSACCHARIDE; MESSENGER RNA; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BLOOD VESSEL PERMEABILITY; CELL COUNT; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOSKELETON; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; LUNG BLOOD VESSEL; LUNG ENDOTHELIUM; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CELLS, CULTURED; CYTOSKELETON; DISEASE MODELS, ANIMAL; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; HORMONE ANTAGONISTS; HUMANS; LIPOPOLYSACCHARIDES; LUNG; LUNG INJURY; MALE; MICE; MICE, INBRED C57BL; PULMONARY ARTERY; RECEPTORS, ATRIAL NATRIURETIC FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856788364     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2011.09.012     Document Type: Article

References (40)

1. Ahluwalia A., MacAllister R.J., Hobbs A.J. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res. Cardiol. 2004, 99:83-89.
2. Anand-Srivastava M.B. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005, 26:1044-1059.
3. Baxter G.F. The natriuretic peptides. Basic Res. Cardiol. 2004, 99:71-75.
4. Birukov K.G., Bochkov V.N., Birukova A.A., Kawkitinarong K., Rios A., Leitner A., Verin A.D., Bokoch G.M., Leitinger N., Garcia J.G. Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac. Circ. Res. 2004, 95:892-901.
5. Birukova A.A., Chatchavalvanich S., Rios A., Kawkitinarong K., Garcia J.G., Birukov K.G. Differential regulation of pulmonary endothelial monolayer integrity by varying degrees of cyclic stretch. Am. J. Pathol. 2006, 168:1749-1761.
6. Birukova A.A., Fu P., Chatchavalvanich S., Burdette D., Oskolkova O., Bochkov V.N., Birukov K.G. Polar head groups are important for barrier protective effects of oxidized phospholipids on pulmonary endothelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L924-L935.
7. Birukova A.A., Cokic I., Moldobaeva N., Birukov K.G. Paxillin is Involved in the Differential Regulation of Endothelial Barrier by HGF and VEGF 2008, Am J Respir Cell Mol Biol.
8. Birukova A.A., Zagranichnaya T., Alekseeva E., Bokoch G.M., Birukov K.G. Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection. J. Cell. Physiol. 2008, 215:715-724.
9. Birukova A.A., Xing J., Fu P., Yakubov B., Dubrovskyi O., Fortune J.A., Klibanov A.M., Birukov K.G. Atrial natriuretic peptide attenuates LPS-induced lung vascular leak: role of PAK1. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299:L652-L663.
10. Curry F.R. Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume. J. Clin. Invest. 2005, 115:1458-1461.
11. Delporte C., Winand J., Poloczek P., Von Geldern T., Christophe J. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line. Eur. J. Pharmacol. 1992, 224:183-188.
12. Doust J.A., Pietrzak E., Dobson A., Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005, 330:625.
13. Eison H.B., Rosen M.J., Phillips R.A., Krakoff L.R. Determinants of atrial natriuretic factor in the adult respiratory distress syndrome. Chest 1988, 94:1040-1045.
14. Furst R., Brueckl C., Kuebler W.M., Zahler S., Krotz F., Gorlach A., Vollmar A.M., Kiemer A.K. Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation. Circ. Res. 2005, 96:43-53.
15. Hollister A.S., Rodeheffer R.J., White F.J., Potts J.R., Imada T., Inagami T. Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog. J. Clin. Invest. 1989, 83:623-628.
16. Imamura T., Ohnuma N., Iwasa F., Furuya M., Hayashi Y., Inomata N., Ishihara T., Noguchi T. Protective effect of alpha-human atrial natriuretic polypeptide (alpha-hANP) on chemical-induced pulmonary edema. Life Sci. 1988, 42:403-414.
17. Irwin D.C., Tissot van Patot M.C., Tucker A., Bowen R. Direct ANP inhibition of hypoxia-induced inflammatory pathways in pulmonary microvascular and macrovascular endothelial monolayers. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L849-L859.
18. Karmpaliotis D., Kirtane A.J., Ruisi C.P., Polonsky T., Malhotra A., Talmor D., Kosmidou I., Jarolim P., de Lemos J.A., Sabatine M.S., Gibson C.M., Morrow D. Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 2007, 131:964-971.
19. Kiemer A.K., Weber N.C., Furst R., Bildner N., Kulhanek-Heinze S., Vollmar A.M. Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ. Res. 2002, 90:874-881.
20. Klinger J.R., Warburton R., Carino G.P., Murray J., Murphy C., Napier M., Harrington E.O. Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. Exp. Cell Res. 2006, 312:401-410.
21. Louzier V., Eddahibi S., Raffestin B., Deprez I., Adam M., Levame M., Eloit M., Adnot S. Adenovirus-mediated atrial natriuretic protein expression in the lung protects rats from hypoxia-induced pulmonary hypertension. Hum. Gene Ther. 2001, 12:503-513.
22. Matsukawa N., Grzesik W.J., Takahashi N., Pandey K.N., Pang S., Yamauchi M., Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:7403-7408.
23. Mitaka C., Hirata Y., Nagura T., Sakanishi N., Tsunoda Y., Amaha K. Plasma alpha-human atrial natriuretic peptide concentration in patients with acute lung injury. Am. Rev. Respir. Dis. 1992, 146:43-46.
24. Mitaka C., Hirata Y., Nagura T., Tsunoda Y., Amaha K. Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest 1998, 114:223-228.
25. Moro C., Galitzky J., Sengenes C., Crampes F., Lafontan M., Berlan M. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J. Pharmacol. Exp. Ther. 2004, 308:984-992.
26. Onuoha G.N., Alpar E.K., Gowar J. Plasma levels of atrial natriuretic peptide in severe burn injury. Burns 2000, 26:449-453.
27. Pandey K.N., Nguyen H.T., Li M., Boyle J.W. Natriuretic peptide receptor-A negatively regulates mitogen-activated protein kinase and proliferation of mesangial cells: role of cGMP-dependent protein kinase. Biochem. Biophys. Res. Commun. 2000, 271:374-379.
28. Pedram A., Razandi M., Levin E.R. Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. J. Biol. Chem. 2002, 277:44385-44398.
29. Potter L.R. Domain analysis of human transmembrane guanylyl cyclase receptors: implications for regulation. Front. Biosci. 2005, 10:1205-1220.
30. Potter L.R., Abbey-Hosch S., Dickey D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 2006, 27:47-72.
31. Rana R., Vlahakis N.E., Daniels C.E., Jaffe A.S., Klee G.G., Hubmayr R.D., Gajic O. B-type natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema. Crit. Care Med. 2006, 34:1941-1946.
32. Rubenfeld G.D., Caldwell E., Peabody E., Weaver J., Martin D.P., Neff M., Stern E.J., Hudson L.D. Incidence and outcomes of acute lung injury. N. Engl. J. Med. 2005, 353:1685-1693.
33. Sakurai H., Nozaki M., Traber K.S., Traber D.L. Atrial natriuretic peptide release associated with smoke inhalation and physiological responses to thermal injury in sheep. Burns 2005, 31:737-743.
34. Schmittgen T.D., Zakrajsek B.A. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J. Biochem. Biophys. Methods 2000, 46:69-81.
35. Su A.I., Wiltshire T., Batalov S., Lapp H., Ching K.A., Block D., Zhang J., Soden R., Hayakawa M., Kreiman G., Cooke M.P., Walker J.R., Hogenesch J.B. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6062-6067.
36. Ueda S., Nishio K., Akai Y., Fukushima H., Ueyama T., Kawai Y., Masui K., Yoshioka A., Okuchi K. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock 2006, 26:134-139.
37. Vollmar A.M., Schulz R. Expression and differential regulation of natriuretic peptides in mouse macrophages. J. Clin. Invest. 1995, 95:2442-2450.
38. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. N. Engl. J. Med. 2000, 342:1334-1349.
39. Xing J., Birukova A.A. ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFalpha. Microvasc. Res. 2010, 79:26-62.
40. Xing J., Moldobaeva N., Birukova A.A. Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction. J. Appl. Physiol. 2011, 110:213-224.